Want the short version?
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
PMCB · NASDAQ · Biological Products, (No Diagnostic Substances)
$3.98−0.585 (−12.83%)
Close of Nov 20, 2026, vs Nov 19 · end-of-day
Pharmacyte Biotech (PMCB) · oqro.io/stocks/PMCB · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
Everything reported about this company, newest first. Each line shows the dates that matter for its source.
Insider trade · Traded Jan 7, 2026 · Filed Jan 7, 2026
CEO purchased ~$33K of PMCB shares in the open marketSourceInsider trade · Traded Jan 5, 2026 · Filed Jan 7, 2026
CEO purchased ~$23K of PMCB shares in the open marketSourceInsider trade · Traded Jan 6, 2026 · Filed Jan 7, 2026
CEO purchased ~$24K of PMCB shares in the open marketSourceInsider trade · Traded Jan 5, 2026 · Filed Jan 7, 2026
Director purchased ~$16K of PMCB shares in the open marketSourceInsider trade · Traded Jan 6, 2026 · Filed Jan 7, 2026
Director purchased ~$16K of PMCB shares in the open marketSourceInsider trade · Traded Jan 7, 2026 · Filed Jan 7, 2026
Director purchased ~$17K of PMCB shares in the open marketSource